Bristol Myers announces FDA approval of Opdivo for treatment of NSCLC

Bristol Myers announced that the FDA approved Opdivo for the treatment of adult patients with resectable non-small cell lung cancer, or NSCLC, and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery – otherwise referred to as perioperative therapy, which is used before and after surgery. The approval is based on results from the CheckMate-77T trial, the company’s second positive Phase 3 randomized trial with an immunotherapy-based combination for the treatment of resectable NSCLC.